Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader

Ellie Ivanova, Cosmin A Tegla, Ekaterina Novikova, Alberto M Herrera, Briana Mullins, Jo-Ann Latkowski, Kenneth B. Hymes, Joyoti Dey, Bin Yang, Ashwin Gollerkeri, Jared Gollob, Sergei B. Koralov

Blood (2022) 140 (Supplement 1): 3557–3558.

https://doi.org/10.1182/blood-2022-156816

Published: 2022

Journal Articles

Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL

Cosmin A Tegla, MD, Alberto M Herrera, MS, Angelina M Seffens, BS, Melania H Fanok, PhD, George Dean, MD, John Kawaoka, MD, Mary E Laird, MD, Yi Fulmer, PhD, Andreas Willerslev-Olsen, PhD, Kenneth B. Hymes, MD, Jo-Ann Latkowski, MD, Niels Odum, MD DMSci, Stefan Feske, MD, Bo Shopsin, MD PhD, Victor Torres, PhD, Marshall E. Kadin, MD, Larisa J Geskin, MD, Sergei B. Koralov, PhD

Blood (2019) 134 (Supplement_1): 659.

https://doi.org/10.1182/blood-2019-131917

Published: 2019

Journal Articles

Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)

Catherine Diefenbach, MD, Linda Lam, PhD, Bruce G. Raphael, MD, Kenneth B. Hymes, MD, Michael L. Grossbard, MD, Tibor Moskovits, MD, Peter Martin, FRCPC, MD MS, Jia Ruan, MD PhD, John P. Leonard, MD, Pratip Chattopadhyay, PhD

Blood (2019) 134 (Supplement_1): 3980.

https://doi.org/10.1182/blood-2019-128366

Published: 2019

Journal Articles

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Jacques Azzi, MD, Frank Cirrone, PharmD, Maher Abdul Hay, MD, David Kaminetzky, MD, Kenneth B. Hymes, MD, Maxim Kreditor, MD, Ahmad-Samer Al-Homsi, MD, Michael L. Grossbard, MD, Catherine Diefenbach, MD, Tibor Moskovits, MD, Shella Saint Fleur-Lominy, MD PhD, Bruce G. Raphael, MD, Raoul Tibes, MD PhD

Blood (2018) 132 (Supplement 1): 5216.

https://doi.org/10.1182/blood-2018-99-117314

Published: 2018

Journal Articles

Final Results of a CTEP Sponsored Phase I Study of Alistertib in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Stefan Klaus Barta, MD MRCP, MS, Noah Kornblum, MD, Bruce G. Raphael, MD, Kenneth B. Hymes, MD, Michael L. Grossbard, MD, Tibor Moskovits, MD, Elizabeth Handorf, Joseph Sparano, MD, Richard Piekarz, MD PhD, Catherine Diefenbach, MD

Blood (2018) 132 (Supplement 1): 4166.

https://doi.org/10.1182/blood-2018-99-116991

Published: 2018

Journal Articles

Hodgkin Lymphoma Patients Demonstrate Evidence of Systemic Perturbation of the Monocyte-Dendritic Cell Axis

Catherine Diefenbach, MD, Bruce G. Raphael, MD, Michael L. Grossbard, MD, Kenneth B. Hymes, MD, Tibor Moskovits, MD, David Kaminetzky, MD, Peter Martin, MD, Jia Ruan, MD PhD, Megan McShea, BA, Leonelle B'etou, MPH, Maryam Bonakdar, Cem Abidoglu, Lina Kozhaya, John P. Leonard, MD, Derya Unutmaz, MD

Blood (2016) 128 (22): 2949.

https://doi.org/10.1182/blood.V128.22.2949.2949

Published: 2016

Journal Articles

Circulating Memory T Cells Isolated from Hodgkin Lymphoma Patients Display Evidence of Exhaustion and Chronic Activation

Catherine S. Diefenbach, MD, Bruce G. Raphael, MD, Kenneth B. Hymes, MD, Tibor Moskovits, MD, David Kaminetzky, MD, Peter Martin, MD, Jia Ruan, MD PhD, Stephanie Lauro, RN, BSN, CCRC, Danielle Banks, CCRP, Krysten Brown, MA, Maryam Bonakdar, Cem Abidoglu, Lina Kozhaya, John P. Leonard, MD, Derya Unutmaz, MD

Blood (2014) 124 (21): 4400.

https://doi.org/10.1182/blood.V124.21.4400.4400

Published: 2014

Journal Articles

STAT3 Serine Phosphorylation and HDAC Inhibition In CTCL

Swati Goel, MBBS, Laura K Fogli, MS, Amy Sun, Melania Fanok, Niels Odum, Kenneth B. Hymes, MD, Sergei B. Koralov, PhD

Blood (2013) 122 (21): 3755.

https://doi.org/10.1182/blood.V122.21.3755.3755

Published: 2013

Journal Articles

Romidepsin in the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): The New York University Cancer Center Experience

Salvia Jain, MD, Kenneth B. Hymes, MD

Blood (2011) 118 (21): 4961.

https://doi.org/10.1182/blood.V118.21.4961.4961

Published: 2011

Journal Articles

Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL)

David J. Straus, MD, Madeleine Duvic, MD, Steven M. Horwitz, MD, Kenneth B. Hymes, MD, Andre Goy, MD, Francisco J. Hernandez-Ilizaliturri, MD, Tatyana Feldman, MD, Brett Wegner, Patricia Myskowski, MD

Blood (2011) 118 (21): 882.

https://doi.org/10.1182/blood.V118.21.882.882

Published: 2011

Journal Articles

Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma.

Brad Pohlman, Ranjana Advani, MD, Madeleine Duvic, MD, Kenneth B. Hymes, MD, Tanin Intragumtornchai, MD, Arnuparp Lekhakula, Ofer Shpilberg, Adam Lerner, MD, Dina Ben-Yehuda, Marie beylot-Barry, Uwe Hillen, Jan Fagerberg, Francine M Foss

Blood (2009) 114 (22): 920.

https://doi.org/10.1182/blood.V114.22.920.920

Published: 2009

Journal Articles

Intravascular Hemolytic Anemia with Acanthocytosis Following Alternative Treatment with Ozone, UV Light, and Perflurocarbon

Kenneth B. Hymes, MD, Chan Huynh, MD

Blood (2008) 112 (11): 5388.

https://doi.org/10.1182/blood.V112.11.5388.5388

Published: 2008

Journal Articles

Zanolimumab, a Fully Human Monoclonal Antibody: Early Results of an Ongoing Clinical Trial in Patients with CD4 + Mycosis Fungoides (MF) Type CTCL (Stage IB-IVB) Who Are Refractory or Intolerant to Targretin and One Other Standard Therapy.

Madeleine Duvic, MD, Youn Kim, M.D., Neil J. Korman, M.D., Erin Boh, M.D., Adam Lerner, M.D., Michael P. Heffernan, M.D., Kenneth B. Hymes, M.D., Theresa Pacheco, M.D., Craig A. Elmets, M.D., Steen Lisby, M.D., Ole Baadsgaard, M.D.

Blood (2006) 108 (11): 2731.

https://doi.org/10.1182/blood.V108.11.2731.2731

Published: 2006

NARROW

Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader

Skin Associated Staphylococcus Aureus Contributes to Disease Progression in CTCL

Evaluation of the Functional Landscape of Systemic Immunity in Classical Hodgkin Using a Novel Single Cell Platform (Isolight)

Midostaurin in Combination with Idarubicin and Cytarabine (3+7) Induction for FLT3 Positive AML - Very High Complete Response Rates and Transition to Allogeneic Transplantation

Final Results of a CTEP Sponsored Phase I Study of Alistertib in Combination with Bortezomib and Rituximab in Relapsed and Refractory Mantle Cell and Low Grade Non-Hodgkin Lymphoma

Hodgkin Lymphoma Patients Demonstrate Evidence of Systemic Perturbation of the Monocyte-Dendritic Cell Axis

Circulating Memory T Cells Isolated from Hodgkin Lymphoma Patients Display Evidence of Exhaustion and Chronic Activation

STAT3 Serine Phosphorylation and HDAC Inhibition In CTCL

Romidepsin in the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma (CTCL): The New York University Cancer Center Experience

Final Results of Phase II Trial of Pegylated Liposomal Doxorubicin (PLD) Followed by Bexarotene (Bex) in Advanced Cutaneous T-Cell Lymphoma (CTCL)

Final Results of a Phase II Trial of Belinostat (PXD101) in Patients with Recurrent or Refractory Peripheral or Cutaneous T-Cell Lymphoma.

Intravascular Hemolytic Anemia with Acanthocytosis Following Alternative Treatment with Ozone, UV Light, and Perflurocarbon

Zanolimumab, a Fully Human Monoclonal Antibody: Early Results of an Ongoing Clinical Trial in Patients with CD4 + Mycosis Fungoides (MF) Type CTCL (Stage IB-IVB) Who Are Refractory or Intolerant to Targretin and One Other Standard Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only